Showing results (111-120 of 134) with videos related to
Sort By:
Pageof 14
Cancer Immunology Research|August 30, 2017
Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell ApoptosisRajeev K Shrimali, Shamim Ahmad, Vivek Verma, et al.Iscience|July 26, 2024
A novel developmental critical period of orexinergic signaling in the primary visual thalamusAnna M Sanetra, Jagoda S Jeczmien-Lazur, Kamil Pradel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancerB L Gause, M Sznol, W C Kopp, et al.Nature Medicine|August 24, 2005
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphomaSattva S Neelapu, Larry W Kwak, Carol B Kobrin, et al.Clinical Immunology (Orlando, Fla.)|December 22, 1999
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patientsJ E Janik, L L Miller, W C Kopp, et al.Blood|May 11, 1999
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatinL L Miller, E L Korn, D S Stevens, et al.Cancer Journal (Sudbury, Mass.)|July 6, 2000
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II studyD L Longo, P L Duffey, J G Gribben, et al.Nanomedicine : Nanotechnology, Biology, and Medicine|May 22, 2018
Early detection of pancreatic cancers in liquid biopsies by ultrasensitive fluorescence nanobiosensorsMadumali Kalubowilage, Obdulia Covarrubias-Zambrano, Aruni P Malalasekera, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2023
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 InsertionsZofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, et al.Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.Pageof 14